Sentinel Lymph Node Biopsy for Periorbital Malignancy

From EyeWiki

All content on Eyewiki is protected by copyright law and the Terms of Service. This content may not be reproduced, copied, or put into any artificial intelligence program, including large language and generative AI models, without permission from the Academy.

Article initiated by:
Carisa E. Bohnak, MD, Deanna Ingrassia-Miano DO, Rona Z Silkiss, MD FACS, Thai Do MD, Dianne Schlachter MD
All contributors:
Jill Wells, MD, Michael T Yen, MD, Nahyoung Grace Lee, MD, William I. Evans M.D., Carisa E. Bohnak, MD, Deanna Ingrassia-Miano DO
Assigned editor:
H. Joon Kim, MD, Annie Moreau, MD
Review:
Assigned status Up to Date
 by Michael T Yen, MD on June 29, 2024.


Sentinel Lymph Node Biopsy for Periorbital Malignancy

Introduction

In metastatic disease, malignant cells can disseminate systemically by one of two pathways: hematogenous or lymphatic. Sentinel Lymph Node (SNLB) Biopsy is a procedure designed to identify potential systemic subclinical or microscopic metastasis from a malignant tumor by identifying their appearance in draining lymph nodes.[1][2][3][4][5][6][7][8][9][10] SNLB has transformed cancer management by allowing providers to detect smaller disease volume compared to traditional modalities such a CT or MRI. SLNB is based on the clinical observation that certain malignancies spread via the lymphatics prior to spreading through the bloodstream. This lymphatic spread often proceeds in a preferential and sequential manner, that is, tumors will metastasize first to a draining lymph node/s within in the region before spreading systemically.[8][9]These draining lymph node/s are referred to as the sentinel lymph nodes (SLNs) and it is important to note that there is often more than one sentinel lymph node.[11] The pattern of this lymphatic drainage from a tumor to regional lymph nodes is often but not always predictable.[6][7]

With the exception of basal cell carcinoma, all malignancies of the ocular adnexa tend to metastasize to regional lymph nodes prior to spreading systemically.[1][4] This is especially important in more aggressive lesions such as merkel cell carcinomas and melanomas where patients may harbor microscopic disease at the time of diagnosis. The reported rate of regional nodal metastasis varies significantly between tumor types and vary even within the same tumor depending on the immune system of the host. The current frequency of regional lymph node metastasis in ocular adnexal tumors are as follows (See Table 1): 15%-41% for conjunctival melanoma, 29% for melanoma of the eyelid, 7% to 20% for sebaceous cell carcinoma, and 1.3% to 24% for squamous cell carcinoma of the eyelid.[3][8][12][13][14][15] For Merkel cell carcinoma of the eyelid, the rate estimated by the largest single study to be 21%, has a reported range of 30-66%.[14]

The detection of a positive sentinel lymph node influences the staging of a patient's disease (based on the American Joint Committee on Cancer tumor, nodes, and metastasis [TMN] staging classification) which directly influences prognosis and potential therapeutic options.[13] In fact, the status of the sentinel lymph node/s has been shown to be the most significant prognostic factor regarding survival and recurrence in patients with cutaneous melanoma.[4] A positive SLNB indicates micrometastatic disease, which may necessitate adjuvant therapy, surgery, and increased frequency of subsequent follow-up evaluations.[16] If the sentinel lymph node(s) are negative, the likelihood of involvement of other nodes or distant metastasis is low. Therefore, sentinel lymph node biopsy can prevent unnecessary complete (radical) lymph node dissections that can carry significant morbidity.

Images depicting both a conjunctival melanoma prior to excisional biopsy (left) and a clinical photograph of Merkel cell carcinoma of the eyelid (right). Both lesions tend to be more aggressive and may harbor micro metastasis at the time of diagnosis. Image left courtesy of Cohen et al and image right courtesy of Author Rona Z Silkiss, MD, FACS.

Periorbital Sentinel Lymph Node Physiology

Lymphatic metastasis has been studied for centuries, dating back to Hippocrates in the 5th century, and later Thomas Bartholin in 1653.[17] The concept of a sentinel lymph node; was first proposed by Gould et al in 1960.[12] [18] Gould and his colleagues observed that patients with parotid tumors seemed to have a single lymph node that served as a “sentinel node” and that this node was reliably the first site of metastatic spread.[12] In the 1970s, Robinson et al introduced the concept of lymphatic mapping through cutaneous lymphoscintigraphy to identify lymphatic drainage pathways and allow for more selective biopsy of a single node or a small number of nodes most likely to contain metastasis. This was critically important because the lymphatic drainage patterns are not always as dependable as anatomically described.[16][19] In the 1990s, Morton et al published a landmark study that proposed the use intraoperative mapping utilizing isosulfan blue dye for cutaneous melanomas. Thus began the modern era of SNLB. The use of radioisotope injections (typically technetium-99m sulfur colloid) for lymphatic mapping further enhanced the ability to detect sentinel nodes.[12] Since then, SNLB has become is standard part in the management of various tumors including breast cancer, melanoma, and other solid neoplasms.

Orbital malignancy in particular has a known predilection for lymphatic spread.[1][2][8][14] The concept of SLNB for patients with conjunctival melanoma was introduced in 2000 by Bita Esmaeli.[1] In 2001, Esmaeli et al reported the first case of SNLB in a patient with conjunctival melanoma and Wilson et al published their data on SLNB in five patients with orbital and ocular adnexal tumors. Since then, there have been numerous studies that have examined the use and outcomes of SLNB for ocular adnexal tumors.[7][8][9][10][12][15][19] There have also been modifications to the traditional lymphatic mapping including use of a smaller volume of Tc 99m (0.2mL) versus 1mL and discontinuing the use of blue dye. [6][7][8][9]

Anatomic Considerations

Periorbital lymph nodes

Malignant periocular and periorbital diseases can cause potential spread to the preauricular, submandibular, parotid, or upper cervical lymph nodes; however there can be significant variation in the lymphatic drainage.[6][7][13] Several studies have examined the lymphatic drainage patterns in primate models, human cadaver studies, healthy humans and in patients with conjunctival melanoma. These are summarized below:

  • Nonhuman primate models have shown that the entire upper eyelid, medial canthus, and lateral lower eyelid lymphatics drain to the parotid and preauricular nodes whereas the medial and central lower eyelid lymphatics drain primarily to the submandibular nodes.
  • Human cadaver studies suggests that the lymphatics from the lateral upper and lower eyelid drain primarily into the parotid and preauricular nodes whereas the medial upper and lower eyelids drain into the submandibular nodes.
  • In cadaver studies, the lateral half of the conjunctiva drains to the preauricular and the medial half drains to the submandibular and deeper cervical lymph nodes.
  • Lymphoscintigraphic mapping of healthy humans discovered that the lymphatics in the upper and lower eyelids (both medial and lateral) drain most frequently into the preauricular nodes (but also the parotid nodes).
  • Conjunctival melanomas localized to the temporal area tends to drain to the preauricular node and the nasal area to the submandibular node


More recent lymphoscintigraphic studies emphasize the preauricular and parotid lymph nodes as common sites for periocular micrometastatic disease.[20]

Given the known variation in drainage patterns, careful clinical evaluation of the preauricular, parotid, submandibular, and cervical nodes is suggested when assessing patients for ophthalmological malignancy.

Indications for Sentinel Lymph Node Biopsy in Periorbital Malignancy

Before SLNB, patients should have negative imaging findings via modalities such as ultrasound and CT.   Patients with imaging suspicious for a disseminated disease are not considered for SLNB as disease spread is already confirmed with less invasive techniques.

Factors that may influence the SLNB results include malignancy type, location, metastatic potential, and disease morphology (See Table 1). Generally accepted criteria are as follows: conjunctival/eyelid melanomas ≥1mm in histologic thickness and/or those with histologic ulceration; cutaneous melanomas at least 1mm thick or <1mm thick but with evidence of histologic ulceration those with >1 mitotic figure per mm2 or Clark level IV (in the case of eyelid skin melanomas); sebaceous cell carcinomas ≥10 mm in width or lesions at stage T2b or higher; squamous cell carcinomas wider than 2cm, locally recurrent or those that have perineural invasion; and merkel cell carcinomas of any size.[13][14][21]

TABLE 1: Periocular Malignancies and SNLB

Malignancy Location Metastatic Occurrence* Indication for SLNB False-Negative SLNB Occurrence* SLNB Detection
Melanoma[14] Eyelid 29%
  • Tumor thickness  ≥1mm
  • Clark level ≥4: melanoma invades reticular dermis or deeper
  • >1 mitotic figures on high-power microscopy
  • Ulceration seen on primary lesion histology
 20.4%

[range: 3.3-44%]

  • Immunohistochemistry

    - S100

    - HMB45

    - MelanA

    - MART-1

  • RT-PCR
Conjunctiva 15-41%
  • Tumor thickness ≥2mm
  • Ulceration seen on primary lesion histology
  • Primary lesion sparing the limbus
  • Locally recurrent primary lesion
 8%
  • Immunohistochemistry

    - S100

    - HMB45

    - MelanA

Sebaceous (Meibomian) Carcinoma[8][14] Eyelid & Conjunctiva 7-20%
  • Tumor stage 2b or higher: diameter >10mm and/or has spread to the full thickness of the eyelid
 16%
  • Immunohistochemistry

    - Adipophilin

    - Perilipin

Squamous Cell Carcinoma[14] Eyelid 1.3-24.3%
  • Tumor diameter >20mm
  • Locally recurrent primary lesion
  • Perineural invasion (typically of cranial nerves V or VII)
 No recordings in the literature at this time
  • Immunohistochemistry

    - Pancytokeratin AE1 & AE3

Conjunctiva 1%
Merkel Cell Carcinoma[14] Eyelid 21%
  • Due to poor prognosis of Merkel Cell Carcinoma, SLNB is controversial
  • A negative SLNB may still warrant prophylactic radiation
 12%
  • Immunohistochemistry

    - Cytokeratin 20

    - Chromogranin

    - Cam5.2

Basal Cell Carcinoma[14] Eyelid No recordings in the literature at this time
  • No indication due to low probability of metastatic disease
 n/a n/a
Information listed is in the context of periorbital disease.  *Statistics are recorded from several publications and should be viewed as estimations based on current literature.


There is significant variation in patient inclusion criteria for who should or who should not be considered for SLNB. For instance, there are studies that include patients with conjunctival melanomas ≥2mm and studies which include conjunctival melanomas <1 mm thick but with histologic ulceration.[15][21]

Photos courtesy of Wilson et al and Cohen et al.On the left, "navigator gamma prove guidance system (United States Surgical Corporation, Norwalk, CT) [A, B] Collimation allows unidirectional guidance during surgery. This facilitates localization of the sentinel node [C]. Persistent activity within sentinel node (arrow) after removal from the surgical field ensures that the proper node has been sampled." On the right, "Handheld γ-probe used to localize the sentinel lymph node."

Methods for Sentinel Lymph Node Biopsy

Prior to the SLNB, a preoperative lymphoscintigraphy can be performed. Fast-uptake radioactive tracer, most commonly technetium 99 sulfur colloid (Tc-99m), is injected at the primary tumor bed; intradermally for eyelid lesions, and subconjunctivally for conjunctival lesions.15  Due to these tissues' proximity to the globe, an ophthalmologist trained in radiotracer handling is recommended to conduct the injection, as opposed to a nuclear medicine technician who traditionally administers radiotracer for distal anatomical assessments.[22]  Next, lymphoscintigraphy is commonly used to map the radiotracer as it disperses lymphatically. Serial radiographic images are taken via a gamma camera every 15 minutes then every 30 minutes thereafter to follow the drainage of the tracer. As in other radiological studies, a specialist in nuclear medicine must review the results and confirm metastatic regions before SLNB.

Once the affected lymph nodes are identified, the lymph node biopsy can be appropriately planned.  Typically, SLNB occurs intraoperatively at the time of primary lesion resection, however, this technique may depend on the localization of SLNs and the need for a multidisciplinary approach. Sentinel lymph node biopsy may also be performed separately following primary tumor removal to allow fo histopathological examination to occur and for more careful patient selection.[14] As in the preoperative mapping stage, 0.3 to 0.4 mCi of filtered technetium (Tc)-99 sulfur colloid in 0.2 mL normal saline is injected in 3 to 4 spots around the lesion approximately 1.5 hours prior to surgery.[8][9] After adequate time is allotted for Tc-99m accumulation in sentinel regions, a handheld transcutaneous gamma probe is used to re-identify nodes of interest intraoperatively.[2]  The sentinel lymph is identified as the lymph node/s that have radioactivity counts at least twice as high as the level of background radioactivity. The node/s are then excised and sent for histological review. The lymph node basin surrounding the sentinel lymph nodes are scanned again to look for any additional nodes with high radioactive uptake and subsequently removed. This process continues until little, or no radioactivity is detectable within the draining lymph node basin.

During histological review, SLNs are typically sectioned using the "bread loaf" approach in 1-2mm sections. Hematoxylin and Eosin (H&E) staining is performed to evaluate for malignant cells. Additionally, various immunohistochemical markers (see Table 1) can also be performed to aid in diagnosis. If malignant cells are detected, more extensive lymph node dissection is performed, and patients can be considered for further adjuvant therapy.[14]

Images courtesy of Savar et al.[9] "B, Single photon emission computed tomography/computed tomography scan for the same patient shows the site of injection of technetium and C, drainage to a level II node."

Studies have also examined the utilization of single photon emission computed tomography/computed tomography to help more precisely localize the SLN.[9][14][18][23][24]Initially, studies utilized a dual-dye technique in which a small amount of isosulfan blue dye (0.2 cm3) to aid in visualization was injected; however, this has become a less commonly utilized practice given the concern of staining the conjunctival surface.[8][15]The use of indocyanine green-guided sentinel lymph node biopsy as an alternative to technetium-99m has been examined in a small number of studies; however, Tc-99m remains standard practice.[25]

Outcomes

The published rate of SNL positivity varies greatly. The largest study to date by Esmaeli et al (2017) evaluated fifty-one patients with ocular adnexal melanoma, 20% of patients had a positive SLNB which was consistent with other studies.[15] This was higher for eyelid margin/eyelid skin melanomas (30%) than patients with conjunctival tumors (13%). Three false negatives were reported in patients who had SNLB performed previously.[21] The reported rate of positivity in sebaceous carcinomas of the eyelid is between 17-20%.[14] Of all the ocular adnexal tumors, experience is most limited with squamous cell carcinomas (SCC) and merkel cell carcinomas (MCC) of the eyelid/conjunctiva. For squamous cell carcinomas of the eyelid and conjunctiva, the positivity rate is between 12.5% -14%; however, for merkel cell carcinoma, the data is insufficient to determine a specific rate for the ocular adnexal region but is approximately 20% for MCC of the head and neck region.[14] The false negative rate is even less established for both tumors. There is at least one reported false negative in a patient with a merkel cell carcinoma of the eyelid, but the data is limited. Regarding SCC, the rate is based on a meta-analysis of head and neck SCC (13.7%).[14] Maalouf et al reported an approximately 12% positivity rate and a 6% false negative rate in a heterogenous population of 17 ocular adnexal tumors (4 merkel cell carcinomas, 8 squamous cell carcinomas, 4 ocular adnexal melanomas, and 1 sebaceous cell carcinoma).[19] In 2020, the American Academy of Ophthalmology published a consensus paper that reviewed 27 published studies reporting an average SLN positivity rate of 16.8% and false negative rate of 4.6%.[26]

Complications and Risks of Periorbital Sentinel Lymph Node Biopsy

The most common complication is a false negative result. Overall, the rate is decreasing and is inversely correlated with the experience of the surgeon performing the procedure. In fact, one institution reports a zero false negative rate over the last 15 years.[27] Though rare, SLNB may be contraindicated in patients with radiotracer allergies.[28] There has also been concern regarding radiation exposure from the technetium; however, a dose of 0.3mCi of technetium-labeled sulfur colloid emits an estimated dose of 0.2 rad (0.002 Gray) during a 6-hour period (assuming successful drainage of the sulfur colloid). This dose is far less than the dose needed to cause cataract formation or radiation retinopathy.[6][14]Another potential complication is blue staining of the ocular adnexal structures. In the initial technique described by Morton et al, blue dye was used to help isolate the SLNs. For the first sixteen patients undergoing SLNB in one study, patients did experience transient staining, though, this dissipated by 24 hours.[8] This has been described in other studies as well.[15] Lastly, rarely, iatrogenic injury to neurovascular complexes can occur with nodal dissection.[8][21] The head and neck areas are highly vascularized regions with multiple neurovascular complexes. Injury to the branches of the facial nerve (CN VII) and trigeminal nerve (CN V) can occur with dissection of the preauricular and parotid areas –a careful dissection may minimize these risks.

"Residual blue dye staining of the conjunctiva." Image courtesy of Cohen et al.

Summary:

The use of SLNB in ocular adnexal tumors has been demonstrated to be a safe and effective way to detect micro metastasis and subclinical disease. Detection of a positive sentinel lymph node has vital prognostic significance. As more data is acquired, and biopsies performed, providers will better understand which patients are better candidates for SNLB and limit the number of false negative results.


References

  1. ↑ 1.0 1.1 1.2 1.3 Esmaeli B. Sentinel lymph node mapping for patients with cutaneous and conjunctival malignant melanoma. Ophthal Plast Reconstr Surg. 2000; 16:170–172.
  2. ↑ 2.0 2.1 2.2 Wilson MW, Fleming JC, Fleming RM, Haik BG. Sentinel node biopsy for orbital and ocular adnexal tumors. Ophthalmic Plast Reconstr Surg. 2001 Sep;17(5):338-44; discussion 344-5. doi: 10.1097/00002341-200109000-00008. PMID: 11642490
  3. ↑ 3.0 3.1 Esmaeli B, Eicher S, Popp J, Delpassand E, Prieto VG, Gershenwald JE. Sentinel lymph node biopsy for conjunctival melanoma. Ophthalmic Plast Reconstr Surg. 2001 Nov;17(6):436-42. doi: 10.1097/00002341-200111000-00010. PMID: 11766025.
  4. ↑ 4.0 4.1 4.2 Esmaeli B. Advances in the management of malignant tumors of the eyelid and conjunctiva: the role of sentinel lymph node biopsy. Int Ophthalmol Clin. 2002 Spring;42(2):151-62. doi: 10.1097/00004397-200204000-00014. PMID: 11914711
  5. ↑ Esmaeli B. Sentinel node biopsy as a tool for accurate staging of eyelid and conjunctival malignancies. Curr Opin Ophthalmol. 2002 Oct;13(5):317-23. doi: 10.1097/00055735-200210000-00005. PMID: 12218463
  6. ↑ 6.0 6.1 6.2 6.3 6.4 Delpassand E. Feasibility of preoperative lymphoscintigraphy for identification of sentinel lymph nodes in patients with conjunctival and periocular skin malignancies. Ophthalmic Plast Reconstr Surg. 2003 Mar;19(2):102-6. doi: 10.1097/01.IOP.0000056146.62409.24. PMID: 12644754.
  7. ↑ 7.0 7.1 7.2 7.3 7.4 Nijhawan N, Ross MI, Diba R, Ahmadi MA, Esmaeli B. Experience with sentinel lymph node biopsy for eyelid and conjunctival malignancies at a cancer center. Ophthalmic Plast Reconstr Surg. 2004 Jul;20(4):291-5. doi: 10.1097/01.iop.0000131733.36054.36. Erratum in: Ophthal Plast Reconstr Surg. 2005 Jan;21(1):10. PMID: 15266143
  8. ↑ 8.00 8.01 8.02 8.03 8.04 8.05 8.06 8.07 8.08 8.09 8.10 Ho VH, Ross MI, Prieto VG, Khaleeq A, Kim S, Esmaeli B. Sentinel Lymph Node Biopsy for Sebaceous Cell Carcinoma and Melanoma of the Ocular Adnexa. Arch Otolaryngol Head Neck Surg. 2007;133(8):820–826. doi:10.1001/archotol.133.8.820
  9. ↑ 9.0 9.1 9.2 9.3 9.4 9.5 9.6 Savar A, Ross MI, Prieto VG, Ivan D, Kim S, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma: experience in 30 patients. Ophthalmology. 2009 Nov;116(11):2217-23. doi: 10.1016/j.ophtha.2009.04.012. Epub 2009 Sep 19. PMID: 19766318
  10. ↑ 10.0 10.1 Savar A, Oellers P, Myers J, Prieto VG, Torres-Cabala C, Frank SJ, Ivan D, Esmaeli B. Positive sentinel node in sebaceous carcinoma of the eyelid. Ophthalmic Plast Reconstr Surg. 2011 Jan-Feb;27(1): e4-6. doi: 10.1097/IOP.0b013e3181ef7450. PMID: 20940661
  11. ↑ National Institute of Health. (n.d.). Sentinel lymph node biopsy. National Cancer Institute. Retrieved April 25, 2022, from https://www.cancer.gov/about-cancer/diagnosis-staging/staging/sentinel-node-biopsy-fact-sheet
  12. ↑ 12.0 12.1 12.2 12.3 12.4 Ling J, Tauscher R, Mehta V, Zhang M, Daniels A, Kohanim S. The Role for Sentinel Lymph Node Biopsy in the Management of Conjunctival Melanoma. Int Ophthalmol Clin. 2017 Winter;57(1):87-101. doi: 10.1097/IIO.0000000000000161. PMID: 27898616.
  13. ↑ 13.0 13.1 13.2 13.3 Pfeiffer ML, Savar A, Esmaeli B. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what have we learned in the past decade? Ophthalmic Plast Reconstr Surg. 2013 Jan-Feb;29(1):57-62. doi: 10.1097/IOP.0b013e31827472c5. PMID: 23299810.
  14. ↑ 14.00 14.01 14.02 14.03 14.04 14.05 14.06 14.07 14.08 14.09 14.10 14.11 14.12 14.13 14.14 14.15 Mendoza PR, Grossniklaus HE. Sentinel lymph node biopsy for eyelid and conjunctival tumors: what is the evidence? Int Ophthalmol Clin. 2015 Winter;55(1):123-36. doi: 10.1097/IIO.0000000000000051. PMID: 25436498; PMCID: PMC4548266.
  15. ↑ 15.0 15.1 15.2 15.3 15.4 15.5 Cohen VM, Tsimpida M, Hungerford JL, Jan H, Cerio R, Moir G. Prospective study of sentinel lymph node biopsy for conjunctival melanoma. Br J Ophthalmol. 2013 Dec;97(12):1525-9. doi: 10.1136/bjophthalmol-2013-303671. Epub 2013 Sep 24. PMID: 24064944; PMCID: PMC3841742.
  16. ↑ 16.0 16.1 Morton, D. L., Thompson, J. F., Cochran, A. J., Mozzillo, N., Nieweg, O. E., Roses, D. F., Hoekstra, H. J., Karakousis, C. P., Puleo, C. A., Coventry, B. J., Kashani-Sabet, M., Smithers, B. M., Paul, E., Kraybill, W. G., McKinnon, J. G., Wang, H.-J., Elashoff, R., & Faries, M. B. (2014). Final trial report of sentinel-node biopsy versus nodal observation in melanoma. New England Journal of Medicine, 370(7), 599–609. https://doi.org/10.1056/nejmoa1310460
  17. ↑ Tanis PJ, Nieweg OE, Valdés Olmos RA, Th Rutgers EJ, Kroon BB. History of sentinel node and validation of the technique. Breast Cancer Res. 2001;3(2):109-12. doi: 10.1186/bcr281. Epub 2001 Jan 23. PMID: 11250756; PMCID: PMC139441.
  18. ↑ 18.0 18.1 Campbell AA, Grob SR, Freitag SK. Controversies in Sentinel Lymph Node Biopsy for Ocular Neoplasms. Int Ophthalmol Clin. 2015 Fall;55(4):73-9. doi: 10.1097/IIO.0000000000000089. PMID: 26322427.
  19. ↑ 19.0 19.1 19.2 Maalouf TJ, Dolivet G, Angioi KS, Leroux A, Genin P, George JL. Sentinel lymph node biopsy in patients with conjunctival and eyelid cancers: experience in 17 patients. Ophthalmic Plast Reconstr Surg. 2012 Jan-Feb;28(1):30-4. doi: 10.1097/IOP.0b013e31822fb44b. PMID: 22262287.
  20. ↑ Pushker, N. (2020). Sentinel lymph node biopsy in eyelid malignancy – a brief update. Delhi Journal of Ophthalmology, 30(4). https://doi.org/10.7869/djo.538
  21. ↑ 21.0 21.1 21.2 21.3 Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B. Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol. 2017 Jun;95(4): e323-e328. doi: 10.1111/aos.13252. Epub 2016 Oct 24. PMID: 27775232.
  22. ↑ Echegoyen, J. C., Hirabayashi, K. E., Lin, K. Y., & Tao, J. P. (2012). Imaging of eyelid lymphatic drainage. Saudi Journal of Ophthalmology, 26(4), 441–443. https://doi.org/10.1016/j.sjopt.2012.08.003
  23. ↑ Vuthaluru S, Pushker N, Lokdarshi G, Kumar R, Bajaj MS, Kashyap S, Mathur S, Chawla B, Khurana S, Ghose S. Sentinel lymph node biopsy in malignant eyelid tumor: hybrid single photon emission computed tomography/computed tomography and dual dye technique. Am J Ophthalmol. 2013 Jul;156(1):43-49. e2. doi: 10.1016/j.ajo.2013.02.015. Epub 2013 Apr 26. PMID: 23628352.
  24. ↑ Remenschneider AK, Dilger AE, Wang Y, Palmer EL, Scott JA, Emerick KS. The predictive value of single-photon emission computed tomography/computed tomography for sentinel lymph node localization in head and neck cutaneous malignancy. Laryngoscope. 2015 Apr;125(4):877-82. doi: 10.1002/lary.25024. Epub 2014 Nov 12. PMID: 25388656.
  25. ↑ Rubinstein TJ, Perry JD, Korn JM, Costin BR, Gastman BR, Singh AD. Indocyanine green-guided sentinel lymph node biopsy for periocular tumors. Ophthalmic Plast Reconstr Surg. 2014 Jul-Aug;30(4):301-4. doi: 10.1097/IOP.0000000000000096. PMID: 24814276.
  26. ↑ Freitag SK, Aakalu VK, Tao JP, Wladis EJ, Foster JA, Sobel RK, Yen MT. Sentinel Lymph Node Biopsy for Eyelid and Conjunctival Malignancy: A Report by the American Academy of Ophthalmology. Ophthalmology. 2020 Dec;127(12):1757-1765. doi: 10.1016/j.ophtha.2020.07.031. Epub 2020 Jul 19. PMID: 32698034.
  27. ↑ Esmaeli B. Re: Freitag et al.: Ophthalmic Technology Assessment: Sentinel lymph node biopsy for eyelid and conjunctival malignancy: a report by the American Academy of Ophthalmology (Ophthalmology. 2020; 127:1757-1765). Ophthalmology. 2021 Jun;128(6): e29. doi: 10.1016/j.ophtha.2021.01.012. Epub 2021 Feb 11. PMID: 33583572.
  28. ↑ Black, E., Nesi, F., Calvano, C., Gladstone, G., & Levine, M. (2012). Smith and Nesi's ophthalmic plastic and reconstructive surgery (Third Ed.). Springer Nature.
Retrieved from "https://eyewiki.org/w/index.php?title=Sentinel_Lymph_Node_Biopsy_for_Periorbital_Malignancy&oldid=108589"
The Academy uses cookies to analyze performance and provide relevant personalized content to users of our website.
Learn more
Powered by MediaWiki
Powered by Canasta
Powered by Semantic MediaWiki